Nov. 23 at 10:47 PM
Attached is a table that documents certain valuation related data points of a pool of newer commercial-stage non-oncology focused bios (those with 1st approvals since 1/1/2020). The table includes a handful of older such bios. We're interested in the 5 on the bottom.
Genuine responses would be appreciated on;
$BCRX For those investors that believe some commercial-stage bios trade in cycles, is BCRX near a bottom?
$TVTX has more than doubled the last 6 month yet still trades at meaningfully lower multiples than peers.
$LGND multiples are "off-the-charts" but investors often cite low forecasts from future royalties including TVTX
$FOLD Are there any updates on the generic?
$APLS ?
This is not investment advice. We're genuinely curious as our club has a major re-balance at year end (we plan for now).
